Z-Alpha Therapeutics

Z-Alpha Therapeutics develops targeted alpha radiotherapeutics based on the isotope astatine-211, which it says has a 7.2-hour half-life, emits one alpha particle per decay, decays to stable lead-207 and can be made on demand from bismuth. It says it has a stable supply of astatine-211 across several continents and its own labelling and linker technology. Its co-founders include chief executive Kevin Bunker, a co-founder of Zentalis Pharmaceuticals, chief technology officer Michael Zalutsky and scientific adviser Martin Pomper; its board includes representatives of OrbiMed, Tybourne Capital, Lilly Asia Ventures and D&D Pharmatech. A February 2026 Asia Business Daily report describes an astatine-211 PSMA-targeting candidate for prostate cancer, as developed by D&D Pharmatech's US affiliate Z-Alpha, says an initial clinical study was run in China and that US or European development was planned for 2026. OrbiMed's portfolio page describes Z-Alpha as Shanghai-based and as having licensed clinical-stage programmes from Zentalis, which differs from the company's current site.